ClinicalTrials.govpublic full text
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
multiple myeloma, transplant eligible, talquetamab, teclistamab, mrd negativity, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 861612
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.